Company intelligence / Profile preview
Nucorion Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
Nucorion Pharmaceuticals is developing a pipeline of anti-cancer and anti-viral small molecule drugs using proprietary liver-targeted prodrug technologies. Their lead assets target chronic and acute hepatitis B, with both in Phase 1 clinical trials. Other pipeline candidates address hepatocellular carcinoma, solid tumors, and hepatitis C at earlier stages. The company’s approach aims to improve efficacy/safety of validated actives for liver-related diseases—especially those with high unmet need in China—and has demonstrated promising preclinical proof-of-concept data
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculeProdrug (Liver-targeting prodrug technology)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Nucorion Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nucorion Pharmaceuticals.